PET/CT vs. CT Scan for Monitoring Metastatic Breast Cancer
Part of Cancer, Skin clinical trials.
This trial compares two types of scans (PET/CT and CT) to see which is better at monitoring metastatic breast cancer. If you are starting your first treatment for breast cancer that has spread to other parts of the body, this study may help determine the best way to track your disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have breast cancer that has spread to other parts of the body, confirmed by a biopsy of the metastasis.
- You are about to start your first treatment for this stage of breast cancer.
- You are able to have regular scans for monitoring.
- You are not pregnant or breastfeeding.
- You do not have an allergy to FDG (a substance used in PET scans).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new PET scan tracer called [68Ga]Ga-PentixaFor to see if it can better detect breast cancer that has spread. You may benefit if you have triple negative breast cancer that has come back or spread, and you are looking for more precise imaging.
This trial tests whether a special PET scan (FDG PET-CT) can better track how well treatment is working for people with advanced breast cancer. It may help doctors choose the best therapy and monitor response over time.
This study uses special PET/MRI scans to see how well breast cancer treatments are working. It aims to find better ways to monitor your cancer and guide your care.
This trial uses a special PET scan to see how well your breast cancer is responding to neoadjuvant therapy (treatment given before surgery). The goal is to help doctors personalize your care by checking if the cancer is shrinking.
This trial studies how an FDG PET/CT scan (a special imaging test that looks for active cancer activity) can be used in people with high-risk primary or recurring breast cancer. It may help doctors better identify areas of concern and guide future care.
This trial uses a special whole-body scan (FDG PET/CT) to see how well first-line chemotherapy is working early in people with metastatic colon/rectal cancer. It may help doctors spot whether treatment is effective sooner, so they can adjust plans if needed.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.